跳至主要内容
临床试验/ISRCTN63456799
ISRCTN63456799已完成未知

Can somatostatin control acute bleeding from oesophageal varices in Schistosoma mansoni patients?

niversity of Antwerp (Belgium)0 个研究点目标入组 20 人开始时间: 2004年12月1日最近更新:
适应症

试验速览

阶段
未知
状态
已完成
发起方
入组人数
20

研究概览

研究设计

研究类型
Interventional

入排标准

性别
All

入选标准

  • Schistosoma mansoni infected adolescent patients with variceal bleeding in the last 24 hours.
  • The inclusion criteria will be established fibrosis due to schistosomiasis of clinical history, physical examination and laboratory findings (and an examination compatible with the presence of portal hypertension due to fibrosis). Clinically active upper gastrointestinal bleeding (haematemesis of fresh or semi fresh blood and/or melena and/or haematochezia) with or without haemodynamic instability (systolic blood pressure < 80 mm Hg and heart rate > 120 bpm) will be selected. Subjects must be male or non-pregnant, non-lactating female subjects. Females of childbearing potential will have to utilize contraception for the duration of the study. Written or verbal documented informed consent will be needed from all subjects.

排除标准

  • Exclusion criteria will include participation by subjects in another investigational study within the last 14 days. Subjects may not undergo treatment with endotherapy, i.e. band ligation, sclerotherapy or other (balloon tamponade). Treatment with somatostatin, vasopressin or their analogues will also be a exclusion criteria. Subjects with end stage liver disease with hepatorenal syndrome, diffuse hepatocellular carcinoma, patent porto-systemic shunts, known diagnosis of non-fibrotic portal hypertension, severe cardiovascular diseases, i.e. acute myocardial infarction and heart failure will be excluded. Concurrent use of metoclopramide is also not advised.

研究者

发起方
niversity of Antwerp (Belgium)

相似试验